A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Solid Biosciences gets $240M for pipeline; Roche expounds on lupus data
Solid Biosciences gets $240M for pipeline; Roche expounds on lupus data
Roche partner Zealand posts Phase 2 data for amylin obesity drug
Roche partner Zealand posts Phase 2 data for amylin obesity drug
Roche, Element and Ultima push toward the $100 genome
Roche, Element and Ultima push toward the $100 genome
Roche gets third pivotal win with MS drug, but liver signal could be a problem
Roche gets third pivotal win with MS drug, but liver signal could be a problem
Roche to stop work on bone health treatment for Duchenne
Roche to stop work on bone health treatment for Duchenne
Paragon's new biotech Korsana tackles Alzheimer's like Roche
Paragon's new biotech Korsana tackles Alzheimer's like Roche
#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
Roche boosts NC factory investment to $2B; Rentschler CEO steps down
Roche boosts NC factory investment to $2B; Rentschler CEO steps down
Roche returns to Chinese biotech MediLink for another ADC pact
Roche returns to Chinese biotech MediLink for another ADC pact
Ollin’s drug clears retinal disease better than Roche’s Vabysmo in Phase 1b trial
Ollin’s drug clears retinal disease better than Roche’s Vabysmo in Phase 1b trial
Charles Fuchs leaves Roche to steer ADC pipeline at Tubulis shortly after $401M Series C
Charles Fuchs leaves Roche to steer ADC pipeline at Tubulis shortly after $401M Series C
Roche's patent deal with Structure; AstraZeneca reports lupus data
Roche's patent deal with Structure; AstraZeneca reports lupus data
Gilead's herpes deal; FDA approvals for Boehringer, Roche
Gilead­'s her­pes deal; FDA ap­provals for Boehringer, Roche Plus, news about Bio­Marin and Cas­sa­va. Gilead opts in­to As­sem­bly...
#SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%
#SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%
Clinical trials tech startup Paradigm raises $78M, acquires part of Roche’s Flatiron
Clinical trials tech startup Paradigm raises $78M, acquires part of Roche’s Flatiron
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page